United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean they're easier to get. Many employers and ...

On Dec. 20, 2024, the FDA approved Zepbound for the treatment of moderate to severe ... That depends on what insurance you have and why the medication was prescribed. Medicare Part D will cover GLP-1 ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

Representatives from Elon Musk's department are working with the Centers for Medicare and Medicaid Services to identify and address inefficiencies and potential fraud. They have gained access to ...

The fourth quarter results showed a 45% increase in revenue, to $13.5 billion, from sales of its GLP-1 drugs Mounjaro, for diabetes, and Zepbound, for weight loss. Mounjaro brought in $11.5 ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...